Plain-English translation of NCT07275073 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is the first-time-in-humans study of , a new medication being tested to treat advanced solid tumors. Researchers want to understand how safe the medication is, how your body processes it, and whether it can help slow or shrink tumors. The study will enroll about 200 patients and includes a dose-escalation phase (testing different amounts) followed by expansion to specific cancer types.
Standard treatments for advanced solid tumors don't work well for everyone, and many patients need new options. This trial is exploring whether this medication could offer hope to people whose cancers have stopped responding to existing therapies or who cannot tolerate current treatments.
You likely qualify if…
You likely don't qualify if…
You will receive as your treatment during the study. The trial starts with a dose-escalation phase where researchers carefully increase the dose in small groups of patients to find the safest and most effective amount. After that, more patients with specific cancer types will receive the medication at the selected dose. You will have regular clinic visits for physical exams, blood tests, and imaging scans to monitor your health and how your tumor responds to treatment. The study lasts several months or longer, depending on how well you tolerate the medication and how your cancer responds.
AI-generated summary from trial data · Aug 4, 2026 · Not medical advice
China